Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net loss	$ (2,120,000)	$ (2,877,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	544,000	1,117,000
Common stock issued for services	282,000	76,000
Bad debt expense	46,000	0
Excess and obsolete inventory	54,000	0
Amortization of right-of-use operating lease assets	60,000	0
Interest expense related to amortization of the discount on note payable	3,000	8,000
Fair value of warrant issued for interest	30,000	0
PPP loan forgiveness	0	(174,000)
Loss on investment in South Korean joint venture	12,000	15,000
Depreciation expense	48,000	6,000
Changes in assets and liabilities:
Accounts receivable	(19,000)	(66,000)
Inventories	(63,000)	(15,000)
Prepaid expenses and other assets	66,000	4,000
Deferred revenue	(7,000)	(89,000)
Lease liability, net	(52,000)	0
Customer deposits	(71,000)	58,000
Net cash used in operating activities	(1,527,000)	(1,864,000)
Cash flows from investing activities
Equipment purchases	(127,000)	(101,000)
Net cash used in investing activities	(127,000)	(101,000)
Cash flows from financing activities
Proceeds from sale of common stock	1,294,000	2,150,000
Repayment of note payable and vehicle loan	(52,000)	0
Repayment by Clyra on inventory line of credit	(18,000)	(10,000)
Proceeds from sale of Clyra Medical preferred stock	1,287,000	0
Proceeds from Clyra Medical convertible note	0	100,000
Net cash provided by financing activities	3,391,000	2,240,000
Net effect of foreign currency translation	(13,000)	(11,000)
Net change in cash	1,724,000	264,000
Cash at beginning of year	1,851,000	962,000
Cash at end of period	3,575,000	1,226,000
Supplemental disclosures of cash flow information
Interest	27,000	7,000
Income taxes	5,000	0
Short-term lease payments not included in lease liability	24,000	78,000
Non-cash investing and financing activities
Equipment added via vehicle loan	80,000	0
Leasehold improvements included in accounts payable	102,000	0
Conversion of Clyra Common Stock to BioLargo Common Stock [Member]
Non-cash investing and financing activities
Conversion of Clyra common stock to BioLargo common stock	100,000	0
Conversion of Intercompany Receivable into Clyra Shares [Member]
Non-cash investing and financing activities
Allocation of noncontrolling interest	1,927,000	631,000
BETI Common Stock [Member]
Cash flows from financing activities
Proceeds from sale of common stock	880,000	0
Entities, Excluding Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	(391,000)	105,000
Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	$ 51,000	$ (32,000)